Literature DB >> 6255555

Production of DTH in the mouse to influenza virus: comparison with conditions for stimulation of cytotoxic T cells.

K N Leung, G L Ada.   

Abstract

The kinetics of sensitization and elicitation of delayed-type hypersensitivity in mice to both infectious and non-infectious preparations of influenza virus was found to be similar to that of some protein antigens and to other viruses. Sensitization was achieved without added adjuvant. Maximum DTH was elicited in the footpad 6 days after sensitization. Adoptive transfer experiments showed that the effector cells were in the Ig-negative fraction of the spleen and were sensitive to anti-theta and complement. A comparison was made of conditions for the generation of DTH activity with cytotoxic T cells. The route of inoculation was important. With a high dose (10(3) HAU) of virus, subcutaneous inoculation was the most efficient and intravenous injection the least efficient for sensitizing for DTH, whereas the reverse was found for cytotoxic T-cell generation. Second, treatment of mice with cyclophosphamide (Cy) had differential effects. Preinjection of a large dose (200 mg/kg) into mice 2 days before sensitization with virus resulted in an increase in the DTH response and a 90% reduction in cytotoxic T-cell activity in the spleens of the treated mice. The Cy-injected mice had reduced (70%) anti-haemagglutinin levels compared with the controls. This may be the explanation for the enhanced DTH response, since transfer of specific antibody to sensitized mice before injection of the eliciting virus substantially reduced the DTH response. Pretreatment with Cy did not affect the generation of DTH effector cells, since spleen cells from these and control mice had similar levels of activity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6255555     DOI: 10.1111/j.1365-3083.1980.tb00049.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  9 in total

1.  Cyclophosphamide and dimethyl dioctadecyl ammonium bromide immunopotentiate the delayed-type hypersensitivity response to inactivated enveloped viruses.

Authors:  R H Smith; B Ziola
Journal:  Immunology       Date:  1986-06       Impact factor: 7.397

2.  Experimental rabies in skunks: effects of immunosuppression induced by cyclophosphamide.

Authors:  K M Charlton; G A Casey; J B Campbell
Journal:  Can J Comp Med       Date:  1984-01

3.  Humoral and cellular responses of mice to infection with a cold-adapted influenza A virus variant.

Authors:  N K Mak; Y H Zhang; G L Ada; G A Tannock
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

4.  The inductive requirements for the primary in vitro generation of delayed-type hypersensitivity response to influenza virus in mice.

Authors:  K N Leung; N K Mak; G L Ada
Journal:  Immunology       Date:  1981-09       Impact factor: 7.397

5.  Sensitization of mice with wild-type and cold-adapted influenza virus variants: immune response to two H1N1 and H3N2 viruses.

Authors:  S J Tao; N K Mak; G L Ada
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

6.  Split T-cell tolerance in herpes simplex virus-infected mice and its implication for anti-viral immunity.

Authors:  A A Nash; N P Ashford
Journal:  Immunology       Date:  1982-04       Impact factor: 7.397

7.  Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions.

Authors:  Y L Lin; B A Askonas
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

8.  Effect of helper T cells on the primary in vitro production of delayed-type hypersensitivity to influenza virus.

Authors:  K N Leung; G L Ada
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

9.  Inhibition of acute experimental allergic encephalomyelitis in mice by colchicine.

Authors:  M J Lyons; R Amador; C Petito; K Nagashima; H Weinreb; J B Zabriskie
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.